Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevalence and Therapy of Rheumatological Adverse Events Due to Immune Checkpoint Inhibitor Therapy including Nivolumab, Ipilimumab, or pembrolizumab

Next Previous
Trial Profile

Prevalence and Therapy of Rheumatological Adverse Events Due to Immune Checkpoint Inhibitor Therapy including Nivolumab, Ipilimumab, or pembrolizumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Gastrointestinal cancer; Head and neck cancer; Lung cancer; Malignant melanoma
  • Focus Adverse reactions

Most Recent Events

  • 03 Jul 2020 New trial record
  • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top